Bo Chen is the founder of Keymed Biosciences. Latest round: IPO. Backed by OrbiMed, Bain Capital.
Bo Chen is the Chairman, Executive Director, and CEO of Keymed Biosciences, a company he founded in 2016. An expert in antibody drug discovery and development with over 20 years of experience, he led Keymed Biosciences to be listed on the main board of the Hong Kong Stock Exchange in July 2021. Previously, he founded Wuhan Huaxin Kangyuan Biopharma Co., Ltd. and Shanghai Junshi Biosciences Co., Ltd., where he was instrumental in developing groundbreaking innovative medicines such as the first domestically-developed PD-1 antibody toripalimab and the first domestically-developed IL-4α humanized monoclonal antibody, Stapokibart Injection, which was approved and launched in September 2024.
Full founder directory · Investor directory · Company funding database · Fundraising library